Primary eosinophilic gastrointestinal disorders (EGID) are immune-mediated chronic morbidities that affect mostly children and young adults, resulting in marked disease burden and low quality of life. Protheragen is the foremost service provider in research on uncommon gastrointestinal disorders such as EGID. We provide an all-in-one solution for preclinical drug development and discovery, tailored to shorten your timeline for developing novel therapy options.

Overview of Eosinophilic Gastrointestinal Disorders (EGID)

Primary eosinophilic gastrointestinal disorders (EGID) consist of a group of diseases with eosinophilic inflammation of particular areas of the bowel in the absence of secondary pathology like infection or reaction to medication.

Recently, based on the location of the inflammation, EGIDs have been classified as eosinophilic esophagitis (EoE) and non-EoE EGIDs. EoE has an estimated incidence of one in two thousand persons; however, it is considered a major contributor to upper gastrointestinal morbidity. Available information regarding the epidemiology of non-EoE EGIDs indicates that they are less common, with a prevalence rate between 3/100,000 and 8/100,000.

Fig.1 Key molecular targets of monoclonal antibodies in EGID. (Rossi, C. M., et al., 2022)

Pathogenesis of Eosinophilic Gastrointestinal Disorders (EGID)

Both atopy and autoimmunity are linked to EGIDs. Activated eosinophils are pathognomonic of EGID, and their infiltration often causes organ dysfunction. It appears that there is a combination of genetic predisposal combined with environmental risk factors and intestinal dysbiosis which leads these multifactorial diseases known as EGIDs to develop, and triggers the development of T-helper type 2 (Th2) inflammation and epithelial barrier dysfunction.

Fig.2 Framework for consensus nomenclature in EGIDs. (Dellon, E. S., et al., 2022)

Therapeutics Development for Eosinophilic Gastrointestinal Disorders (EGID)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

At Protheragen, our integrated services include the entire scope of preclinical work. We not only propel the innovation of new therapeutic targets and validate drug candidates but also conduct advanced diagnostic studies to discover critical biomarkers and illuminate disease processes. This allows for the creation of effective therapeutic approaches for rare gastrointestinal diseases. Our disease model development systems recapitulate the pathobiological features of EGID, thus serving as an adequate platform for mechanistic studies and therapeutic evaluations.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services for Eosinophilic Gastrointestinal Disorders (EGID)

The impact of animal models on the progress of EGID research is undeniable. These allow researchers to study the immunological and molecular facets associated with the recruitment, activation, and tissue remodeling of eosinophils. With advances in technology, our company provides bespoke animal model development services to target specific areas of research.

Genetically Engineered Models

Transgenic models that overexpress cytokines lead to increased eosinophil production and recruitment, simulating the inflammatory response observed in EGID.

Optional models:

• IL-5 overexpression model
• Eotaxin-1 overexpression model
• Other models

Induced Model Development

Specific sensitization and antigen challenges lead to gastrointestinal eosinophilia and inflammation similar to the manifestations of EGID.

Optional models:

• Peanut protein extract (PPE)-induced model
• Ovalbumin (OVA)-induced model
• Other models

Protheragen incorporates specialized preclinical services that assess a candidate's pharmacokinetics and safety to aid in minimizing risks and facilitate easier transitions into human trials. Our unique combination of profound scientific knowledge and modern technology makes us the most reliable partner in altering the terrain of rare gastrointestinal illness research. For inquiries about our services, please reach out to us for further details and pricing information.

References

• Rossi, Carlo Maria et al. "Primary eosinophilic gastrointestinal disorders and allergy: Clinical and therapeutic implications." Clinical and translational allergy 12.5 (2022): e12146.
• Dellon, Evan S et al. "International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature." Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 20.11 (2022): 2474-2484.e3.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.